AU2013312102B2 - C17-heteroaryl derivatives of oleanolic acid and methods of use thereof - Google Patents

C17-heteroaryl derivatives of oleanolic acid and methods of use thereof Download PDF

Info

Publication number
AU2013312102B2
AU2013312102B2 AU2013312102A AU2013312102A AU2013312102B2 AU 2013312102 B2 AU2013312102 B2 AU 2013312102B2 AU 2013312102 A AU2013312102 A AU 2013312102A AU 2013312102 A AU2013312102 A AU 2013312102A AU 2013312102 B2 AU2013312102 B2 AU 2013312102B2
Authority
AU
Australia
Prior art keywords
compound
disease
groups
substituted
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013312102A
Other languages
English (en)
Other versions
AU2013312102A1 (en
Inventor
Christopher F. Bender
Xin Jiang
Melean Visnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of AU2013312102A1 publication Critical patent/AU2013312102A1/en
Application granted granted Critical
Publication of AU2013312102B2 publication Critical patent/AU2013312102B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Lubricants (AREA)
AU2013312102A 2012-09-10 2013-09-10 C17-heteroaryl derivatives of oleanolic acid and methods of use thereof Active AU2013312102B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699199P 2012-09-10 2012-09-10
US61/699,199 2012-09-10
PCT/US2013/059015 WO2014040056A1 (en) 2012-09-10 2013-09-10 C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2013312102A1 AU2013312102A1 (en) 2015-03-12
AU2013312102B2 true AU2013312102B2 (en) 2018-03-08

Family

ID=49253401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013312102A Active AU2013312102B2 (en) 2012-09-10 2013-09-10 C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Country Status (28)

Country Link
US (1) US20140088163A1 (enExample)
EP (1) EP2892911B1 (enExample)
JP (1) JP6272870B2 (enExample)
KR (1) KR102237364B1 (enExample)
CN (1) CN104768965B (enExample)
AU (1) AU2013312102B2 (enExample)
BR (1) BR112015005200B1 (enExample)
CA (1) CA2882417C (enExample)
CY (1) CY1119762T1 (enExample)
DK (1) DK2892911T3 (enExample)
EA (1) EA029069B1 (enExample)
ES (1) ES2644615T3 (enExample)
HR (1) HRP20171565T1 (enExample)
HU (1) HUE036797T2 (enExample)
IL (1) IL237638B (enExample)
IN (1) IN2015DN01547A (enExample)
LT (1) LT2892911T (enExample)
ME (1) ME02911B (enExample)
MX (1) MX366954B (enExample)
NZ (1) NZ705213A (enExample)
PL (1) PL2892911T3 (enExample)
PT (1) PT2892911T (enExample)
RS (1) RS56563B1 (enExample)
SG (1) SG11201501800UA (enExample)
SI (1) SI2892911T1 (enExample)
SM (1) SMT201700501T1 (enExample)
WO (1) WO2014040056A1 (enExample)
ZA (1) ZA201501203B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI492745B (zh) 2008-01-11 2015-07-21 Reata Pharmaceuticals Inc 合成的三萜系化合物及其使用於治療疾病之方法
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
MX2010011435A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
NZ612788A (en) 2010-12-17 2015-10-30 Reata Pharmaceuticals Inc Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
SI3444261T1 (sl) 2012-04-27 2021-04-30 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivat bardoksolon metila, njegovi farmacevtski sestavki in polimorfi za uporabo pri zdravljenju določenih stanj
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY35534A (es) 2013-04-24 2014-10-31 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
NZ734292A (en) 2015-02-12 2022-09-30 Reata Pharmaceuticals Inc Imidazolyl tricyclic enones as antioxidant inflammation modulators
MX386256B (es) 2015-09-23 2025-03-18 Reata Pharmaceuticals Inc Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
WO2019055119A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MX2020002884A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
IL279348B2 (en) 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
MX2021003643A (es) * 2018-09-28 2021-08-19 Sichuan Haisco Pharmaceutical Co Ltd Derivados de terpenoides y usos de los mismos.
WO2021016191A1 (en) * 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
RU2020130238A (ru) 2020-03-31 2022-03-14 Феникс Байотекнолоджи, Инк. Способ и композиции для лечения коронавирусной инфекции
JP7214696B2 (ja) * 2020-10-01 2023-01-30 一般財団法人 化学物質評価研究機構 新規in vitro皮膚感作性試験法
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
US20240140986A1 (en) 2021-01-18 2024-05-02 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6974801B2 (en) * 2002-05-13 2005-12-13 The Trustees Of Dartmounth College Inhibitors and methods of use thereof
TWI492745B (zh) 2008-01-11 2015-07-21 Reata Pharmaceuticals Inc 合成的三萜系化合物及其使用於治療疾病之方法
EA022588B1 (ru) * 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
EP2683731B1 (en) * 2011-03-11 2019-04-24 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof

Also Published As

Publication number Publication date
SI2892911T1 (sl) 2017-12-29
EA029069B1 (ru) 2018-02-28
US20140088163A1 (en) 2014-03-27
CN104768965B (zh) 2018-05-11
HUE036797T2 (hu) 2018-07-30
CY1119762T1 (el) 2018-06-27
IL237638B (en) 2020-04-30
KR102237364B1 (ko) 2021-04-06
ES2644615T3 (es) 2017-11-29
CN104768965A (zh) 2015-07-08
KR20150053982A (ko) 2015-05-19
EP2892911A1 (en) 2015-07-15
HK1211295A1 (en) 2016-05-20
RS56563B1 (sr) 2018-02-28
LT2892911T (lt) 2017-11-10
PL2892911T3 (pl) 2018-03-30
IL237638A0 (en) 2015-04-30
MX2015003078A (es) 2015-07-14
ZA201501203B (en) 2021-08-25
DK2892911T3 (en) 2017-10-23
HRP20171565T1 (hr) 2017-12-15
SMT201700501T1 (it) 2017-11-15
JP2015529227A (ja) 2015-10-05
NZ705213A (en) 2018-07-27
JP6272870B2 (ja) 2018-01-31
PT2892911T (pt) 2017-11-02
BR112015005200B1 (pt) 2022-07-05
SG11201501800UA (en) 2015-04-29
EP2892911B1 (en) 2017-08-30
CA2882417A1 (en) 2014-03-13
BR112015005200A2 (enExample) 2017-08-15
MX366954B (es) 2019-07-31
IN2015DN01547A (enExample) 2015-07-03
WO2014040056A1 (en) 2014-03-13
CA2882417C (en) 2021-04-20
EA201590539A1 (ru) 2015-08-31
ME02911B (me) 2018-10-20
AU2013312102A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
AU2013312102B2 (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CA2822071C (en) Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US10898499B2 (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AU2013312106B2 (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) C13-hydroxy derivatives of oleanolic acid and methods of use thereof
KR102101774B1 (ko) 바독솔론 메틸의 2,2-다이플루오로프로피온아미드 유도체, 그의 다형태 및 사용 방법
US9290536B2 (en) C4 monomethyl triterpenoid derivatives and methods of use thereof
CA2974726A1 (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
KR20220044942A (ko) C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
JP2024504637A (ja) 合成ウルソール酸誘導体及びその使用方法
HK1211295B (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)